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Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type
2‐mediated inflammatory disease associated with significant clinical, social, and eco-
nomic burdens and high unmet therapeutic need. Dupilumab, a fully human mono-
clonal antibody targeting the interleukin‐4 receptor α (IL‐4Rα) subunit, demonstrated
efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic der-
matitis and asthma). We now report the local effects of dupilumab on type 2 inflam-
matory biomarkers in nasal secretions and nasal polyp tissues of patients with
CRSwNP in a randomized, placebo‐controlled, phase 2 trial (NCT01920893).
Methods: Cytokines, chemokines, and total immunoglobulin E (IgE) levels were measured
using immunoassay techniques in nasal secretions and nasal polyp tissue homogenates of
CRSwNP patients receiving dupilumab 300 mg or placebo weekly for 16 weeks.
Results: With dupilumab, type 2 biomarker concentrations decreased in nasal secre-
tions (least squares mean area under the curve from 0 to 16 weeks for the change from
baseline) vs placebo for eotaxin‐3 (−30.06 vs −0.86 pg/mL; P = 0.0008) and total IgE
(−7.90 vs −1.86 IU/mL; P = 0.022). Dupilumab treatment also decreased type 2
biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophilic cationic
protein (P = 0.008), eotaxin‐2 (P = 0.008), eotaxin‐3 (P = 0.031), pulmonary and
activation‐regulated chemokine (P = 0.016), IgE (P = 0.023), and IL‐13 (P = 0.031).
Conclusions: Dupilumab treatment reduced multiple biomarkers of type 2 inflamma-
tion in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating
that antagonism of IL‐4Rα signaling suppresses IL‐4‐/IL‐13‐dependent processes,
such as mucosal IgE formation, as well as the expression of chemokines attracting
inflammatory cells to the nasal mucosa.
Abbreviations: AD, atopic dermatitis; AUC0‐16, area under the concentration-vs-time curve from time of first treatment to Week 16; CCL, C-C motif chemokine ligand; CI, confidence
interval; CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyposis; CT, computed tomography; ECP, eosinophil cationic protein; ELISA, enzyme-linked immunosorbent
assay; IgE, immunoglobulin E; IL, interleukin; IL-4Rα, interleukin-4 receptor alpha; IL-13Rα1, interleukin-13 receptor alpha 1; IU, international units; LS, least squares; mAb, monoclonal
antibody; MFNS, mometasone furoate nasal spray; NPS, nasal polyp score; PARC, pulmonary and activation-regulated chemokine; PNIF, peak nasal inspiratory flow; QoL, quality of life; SD,
standard deviation; SE, standard error; SNOT-22, 22-item Sino-Nasal Outcome Test; TARC, thymus and activation-regulated chemokine; Th2, T helper type 2 cell; TNF-α, tumor necrosis
factor alpha; UPSIT, University of Pennsylvania Smell Identification Test; VAS, visual analog scale.
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1 | INTRODUCTION
Chronic rhinosinusitis (CRS) affects 11%‐15% of the general popula-
tion and causes a considerable socioeconomic burden.1,2 CRS is a
heterogeneous inflammatory disease with two distinct clinical pre-
sentations based on pathophysiology and histology.3 CRS without
nasal polyposis is a mainly neutrophilic disease with local elevations
in T helper type 1‐derived cytokines, whereas CRS with nasal poly-
posis (CRSwNP) is characterized by type 2/T helper type 2 cell (Th2)
inflammation, with marked infiltration of eosinophils and mast cells
in the mucosa and polyp tissue.4 Increased concentrations of eosino-
phil cationic protein (ECP; a marker of activated, degranulated eosi-
nophils), eotaxins, total immunoglobulin E (IgE), and interleukin (IL)‐4,
IL‐5, and IL‐13 have been observed in the serum, plasma, and nasal
polyp tissue of patients with CRSwNP.5-7 Type 2 innate lymphoid
cells8,9 and type 2/Th2 lymphocytes10 accumulate in nasal polyps
and mucosa of CRSwNP patients and secrete IL‐4, IL‐5, and
IL‐13,11,12 key drivers of type 2 inflammation, which also play roles
in CRSwNP‐associated diseases such as aspirin‐exacerbated respira-
tory disease and asthma. Another feature of CRSwNP is the
presence of mucosal B cells and plasma cells that secrete IgE,13,14
providing evidence for local IL‐4‐modulated switching of Ig class.
The current standard of care for CRSwNP is focused on control-
ling inflammation and, depending on disease severity, consists of
intranasal corticosteroid spray or drops, nasal saline lavage, short
courses of oral corticosteroids, antibiotics, and functional endoscopic
sinus surgery.2 A subgroup of patients with CRSwNP does not
respond well to the current standard of care and has a rapid relapse
of polyp regrowth after surgery.15 Blocking the underlying immuno-
logical pathomechanisms with monoclonal antibodies (mAbs) target-
ing IL‐4, IL‐5, and IL‐13 has shown promising results in these
patients.16,17 In clinical trials, omalizumab, a mAb that recognizes IgE,
significantly reduced nasal polyp size and showed improvement in
both upper and lower airway functions in patients with CRSwNP;18
mepolizumab, a mAb targeting IL‐5, significantly reduced nasal polyp
size and computed tomography (CT) scores in patients with severe
nasal polyposis.19
IL‐4 and IL‐13 are key drivers of type 2‐mediated inflammation;
these cytokines have structural similarities and signal via the IL‐4
Type II heterodimeric receptor complex composed of IL‐4 receptor
alpha (IL‐4Rα) and IL‐13 receptor alpha 1 (IL‐13Rα1). IL‐4 also signals
via the IL‐4 Type I heterodimeric receptor, composed of the IL‐4Rα
subunit and the common gamma chain. IL‐4 and IL‐13 have
overlapping functions, but can demonstrate varying degrees of speci-
ficity in inducing type 2 inflammation based on the relative cellular
distribution of the Type I and II receptors. IL‐4 predominantly
controls IgE class switching, Th2 lymphocyte differentiation, and
upregulation of IgE receptors on the surfaces of mast cells, basophils,
and B lymphocytes.20,21 In contrast, IL‐13 is thought to have a
greater role in stimulating mucus hypersecretion, airway hyperre-
sponsiveness and subepithelial fibrosis, and secretion of chemokines
such as eotaxins.21 Both IL‐4 and IL‐13 induce secretion of thymus
and activation‐regulated chemokine (TARC) and pulmonary and acti-
vation‐regulated chemokine (PARC), which attract and activate
inflammatory cells.22,23 Based on what is known about the overlap-
ping functions of IL‐4 and IL‐13, targeting signaling via both cytoki-
nes may be beneficial in patients with type 2‐driven disease.
Dupilumab is a fully human VelocImmune®‐derived mAb24,25 that
binds specifically to IL‐4Rα, the shared α chain subunit of the IL‐4
and IL‐13 receptors, inhibiting signaling of both IL‐4 and IL‐13. These
cytokines have been implicated in numerous type 2 atopic/allergic
diseases, including asthma and atopic dermatitis (AD), which are
often associated as comorbidities.26 Placebo‐controlled clinical stud-
ies have demonstrated efficacy of dupilumab in both AD and
asthma; asthma patients experienced significantly reduced exacerba-
tion rates and improved lung function,27,28 as well as reduced oral
glucocorticoid use,28 and AD patients experienced significantly
reduced disease severity and pruritus and improved quality of life
(QoL).29-31 Dupilumab had an acceptable safety profile and was well
tolerated in all of these trials. Dupilumab is approved in the Euro-
pean Union, USA, Japan, and other countries for the treatment of
adults with inadequately controlled moderate‐to‐severe AD.
In a randomized, double‐blind, placebo‐controlled phase 2 study of
dupilumab in patients with CRSwNP with and without asthma,32 the
dupilumab group experienced significant improvement in endoscopic,
radiographic, and QoL endpoints relative to placebo. These clinical
changes were accompanied by a statistically significant reduction in
circulating concentrations of the type 2 biomarkers total IgE and
eotaxin‐3. Transient increases in blood eosinophil count were
observed in some patients after dupilumab treatment initiation. In
addition to the main study assessments of blood and serum, assess-
ments of the effect of dupilumab on nasal secretions and nasal polyp
tissues were performed in a substudy of this trial. Here, we report the
local effect of dupilumab on total IgE levels and markers of eosinophi-
lic inflammation in nasal secretions and polyp tissues from patients
with CRSwNP.
2 | METHODS
2.1 | Study design and population
This randomized, double‐blind, placebo‐controlled, parallel‐group
study was conducted in the USA and Europe between August 2013
and August 2014 (ClinicalTrials.gov Identifier: NCT01920893).32
The study was conducted following ethical principles in accor-
dance with the Declaration of Helsinki, International Conference on
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Harmonisation guidelines, and Good Clinical Practice. All study docu-
ments and procedures were approved by the appropriate institutional
review boards and ethics committees at each study site; each patient
provided written informed consent before study participation. Eligible
patients were aged 18‐65 years with bilateral nasal polyposis and
chronic symptoms of sinusitis despite intranasal corticosteroid treat-
ment lasting ≥2 months. Patients were required to have bilateral
endoscopic nasal polyp score (NPS) ≥5 (maximum score = 8) with
≥2 polyps per nostril and to exhibit ≥2 of the following prior to
screening: nasal obstruction or discharge, facial pain or pressure, or a
reduced or lost sense of smell. Exclusion criteria included previous
participation in dupilumab clinical trials and treatment with systemic
corticosteroids, mAbs, immunosuppressive treatments, or anti‐IgE
therapy during the 2‐month pre‐screening period.32
2.2 | Study treatments
After 4 weeks of treatment with mometasone furoate nasal spray
(MFNS; 100 mg/nostril twice daily), 60 patients were randomly
allocated (1:1) to receive a 600 mg loading dose of dupilumab
followed by 16 weeks of 300 mg dupilumab (n = 30) or matched
placebo (n = 30).32 MFNS was continued at a stable dose throughout
the study, and inhaled asthma control therapies were allowed.
2.3 | Study outcomes
Primary and secondary endpoints in the overall population have
been previously reported32 and are described in detail in Table S1.
The primary efficacy endpoint was mean change in bilateral endo-
scopic NPS from baseline to Week 16. Secondary endpoints included
change in Lund‐Mackay CT score, percentage of maxillary sinus
volume occupied by disease, 22‐item Sino‐Nasal Outcome Test
(SNOT‐22) score, University of Pennsylvania Smell Identification Test
(UPSIT) score, and peak nasal inspiratory flow, as well as patient‐
rated nasal congestion or obstruction, anterior and posterior
rhinorrhea, loss in sense of smell, nocturnal awakenings, and overall
symptom severity. Safety outcomes were assessed as previously
described.32
GRAPHICAL ABSTRACT
• Dupilumab reduced multiple type 2 inflammation biomarkers in nasal secretions and polyp tissues of patients with chronic rhinosinusitis with
nasal polyposis, including total IgE and chemoattractants for inflammatory cells
• Local reductions in type 2 biomarkers were consistent with overall, parallel improvements in nasosinal symptoms and reductions in polypoid
tissue
• These findings suggest that inhibition of IL-4/IL-13 signaling via dupilumab-mediated blockade of IL-4Rα can suppress underlying inflamma-
tion of nasal polyposis, leading to clinical benefits
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2.4 | Sample collection
Nasal secretion samples were collected from 60 patients (n = 30 pla-
cebo, n = 30 dupilumab) in the outpatient clinic on Day 1, and then
every 4 weeks. IVALON® Post‐Op Sinus Packings (Fabco®, New
London, CT, USA) were inserted bilaterally into the nasal cavities for
5 minutes. The two packings were transferred to a tube, and the
adsorbed analytes were then eluted from the packings by adding
3 mL of saline (0.9% NaCl) followed by centrifugation. The super-
natant aliquots were stored at −70°C. Nasal polyp biopsies were col-
lected with forceps from 14 patients at baseline; 12 of these
patients provided a second biopsy at Week 16 (n = 4 placebo, n = 8
dupilumab). Fresh tissue biopsies were weighed, snap‐frozen in liquid
nitrogen, and stored at −80°C. Pharmacodynamic measurements of
blood eosinophil count, total serum IgE, serum TARC, and plasma
eotaxin‐3 concentrations were collected as previously described.32
2.5 | Measurement of cytokines and total IgE in
nasal secretions
Concentrations of eotaxin‐3, total IgE, and ECP in nasal secretions
were assayed in saline eluates from nasal swabs and reported with-
out further normalization. No additional biomarkers were measured
in nasal secretions. Eotaxin‐3 was analyzed using a human C‐C motif
chemokine ligand (CCL) 26 / eotaxin‐3 enzyme‐linked immunosorbent
assay (ELISA) (Quantikine ELISA Kit®, R&D Systems, Minneapolis,
MN, USA) according to manufacturer instructions. Total IgE and ECP
concentrations were analyzed using the ImmunoCAP® fluorescent
enzyme immunoassay (Phadia AB, Uppsala, Sweden) according to
manufacturer instructions.
2.6 | Measurement of cytokines, total IgE, and ECP
concentrations in tissue homogenates
Analysis of biomarker levels in the tissue of nasal polyps was carried
out as previously described.5 To create tissue homogenates, the
tissue was disrupted at 50 Hz for 2 minutes with the Tissue Lyser
LT (Qiagen Benelux, Antwerp, Belgium), and 1 mL 0.9% NaCl in
the presence of cOmplete™, an EDTA‐free protease inhibitor
(Roche Diagnostics Belgium, Vilvoorde, Belgium), per 0.1 g of tissue
was added. Homogenates were centrifuged at 1800 × g for
10 minutes at 4°C. Supernatants were removed and stored at −25°C
until analysis.
All supernatants were analyzed for the presence of cytokines,
chemokines, ECP, and total IgE. Total IgE and ECP levels were mea-
sured using the UniCAP system (Thermo Fisher Scientific, Phadia,
Groot‐Bijgaarden, Belgium) according to manufacturer instructions.
Cytokines were assayed using the Luminex Performance Assay (IL‐4,
IL‐5, IL‐17, tumor necrosis factor alpha [TNF‐α], IL‐10, IL‐1β, IL‐6,
and vascular endothelial growth factor) and Luminex Screening
TABLE 1 Baseline characteristics and clinical responses in the biopsy subgroup
Baseline and change from baseline at Week 16




















Bilateral endoscopic NPS 6.25 (0.50) −0.77 (0.85) 5.63 (1.19) −1.83 (0.59) −1.06 (−3.43, 1.31) 0.3391
Lund–Mackay total score 18.25 (3.95) 1.10 (1.49) 18.13 (4.76) −9.52 (1.01) −10.62 (−14.70, −6.54) 0.0005
Percentage of maxillary sinus
volume occupied by disease
72.20 (24.50) 6.46 (9.03) 61.54 (25.30) −33.43 (5.98) −39.89 (−64.38, −15.39) 0.0063
PNIF (AM) 108.21 (88.57) 0.11 (21.35) 108.38 (66.18) 57.36 (15.28) 57.25 (−2.05, 116.54) 0.0568
SNOT‐22 score 42.50 (25.89) −0.60 (7.49) 45.50 (13.61) −32.11 (5.68) −31.52 (−55.12, −7.91) 0.0177
Sinusitis symptom severity
assessed on VAS, cm
6.20 (1.84) 1.13 (1.41) 5.46 (3.02) −3.65 (0.77) −4.78 (−8.99, −0.58) 0.0332
Sense of smell assessed by UPSIT 12.00 (2.16) −2.27 (3.58) 14.38 (8.60) 9.84 (2.61) 12.11 (1.74, 22.48) 0.0277
Nasal congestion or obstruction (AM) 1.61 (0.66) −0.11 (0.38) 1.82 (0.57) −0.93 (0.29) −0.81 (−1.90, 0.27) 0.1220
Posterior rhinorrhea (AM) 2.32 (0.47) −0.03 (0.31) 1.20 (1.03) −0.64 (0.21) −0.61 (−1.52, 0.30) 0.1650
Serum total IgE, IU/mL 151.75 (125.84) 10.47 (17.04) 142.50 (119.29) −61.17 (13.92) −71.63 (−124.94, −18.33) 0.0163
Serum TARC, pg/mL 425.09 (305.46) 36.12 (108.45) 441.94 (256.06) 4.94 (97.00) −31.18 (−387.31, 324.96) 0.8375
Plasma eotaxin‐3,* pg/mL 56.75 (14.78) 7.86 (6.24) 65.70 (30.70) −20.26 (5.24) −28.12 (−48.03, −8.21) 0.0131
Blood eosinophil count, × 109/L 0.29 (0.18) 0.03 (0.08) 0.32 (0.20) −0.04 (0.06) −0.07 (−0.38, 0.24) 0.5199
AM, in the morning; CI, confidence interval; IgE, immunoglobulin E; IU, international units; LS, least squares; MFNS, mometasone furoate nasal spray;
NPS, nasal polyp score; PNIF, peak nasal inspiratory flow; SD, standard deviation; SE, standard error; SNOT‐22, 22‐item Sino‐Nasal Outcome Test;
TARC, thymus and activation‐regulated chemokine; UPSIT, University of Pennsylvania Smell Identification Test; VAS, visual analog scale.
*For plasma eotaxin‐3 data, heterogeneous compound symmetry covariance structure was used instead of unstructured covariance structure, as the
model with unstructured covariance structure does not converge.
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Human Assay (IL‐13, IL‐33, TARC [CCL17], eotaxin‐3 [CCL26],
eotaxin‐2 [CCL24], eotaxin‐1 [CCL11], and PARC [CCL18]) (R&D
Systems Belgium), according to manufacturer instructions.
2.7 | Statistical analyses
Descriptive statistics were used for demographics and baseline
characteristics. For biomarkers in nasal secretions, the areas under the
concentration‐vs‐time curves from time of first treatment to Week 16
(AUC0–16) for the change from baseline were estimated by trapezoidal
analysis. Comparison of treatment effects from an analysis of covari-
ance model was based on least squares (LS) mean differences in
AUC0-16 between patients in the dupilumab group vs the placebo group
(with 95% confidence intervals [CI] and P values). The model included
AUC0-16 as the response variable, and treatment, stratification factor
(comorbid asthma, biopsy performed), and baseline biomarker value as
the covariates. Since the number of placebo‐treated patients who were
successfully biopsied was small (n = 4), dupilumab treatment effect on
biopsy biomarkers was assessed as change from baseline, analyzed
using the Wilcoxon matched‐pairs signed‐rank test, in addition to a
comparison of dupilumab vs placebo, which was analyzed using the
Mann‐Whitney U test. P < 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Study patients
The baseline clinical characteristics of the overall study population
were similar to those of patients with biopsy data available, except
for numerical differences between posterior rhinorrhea in the morn-
ing (Table 1, Table S2). Baseline demographics and/or clinical charac-
teristics were also comparable between treatment groups in both
the overall population and biopsy subgroup, except for numerical dif-
ferences between total IgE in serum, and ECP and total IgE in nasal
secretions (overall population), and posterior rhinorrhea in the morn-
ing (biopsy subgroup) (Table 1, Table S2). The majority of patients in
both the placebo (80%) and dupilumab (83.3%) groups completed
the study.32 Fourteen patients provided biopsies at baseline, 12 of
whom also provided biopsies at Week 16.
3.2 | Safety
Safety outcomes were previously reported in the overall population
of this study.32 The most common treatment‐emergent adverse
events were mild‐to‐moderate nasopharyngitis, injection‐site reac-
tions, and headache, and were reported more frequently in the dupi-
lumab treatment group vs placebo.
3.3 | Nasal secretion analysis
Dupilumab treatment was associated with overall decreases in
nasal secretion concentrations of eotaxin‐3, total IgE, and ECP
F IGURE 1 Biomarker concentrations in nasal secretions from
patients with CRSwNP in the overall study population. Mean
changes from baseline to Week 16 in (A) total IgE, (B) eotaxin‐3,
and (C) ECP concentrations. ECP, eosinophil cationic protein; IgE,
immunoglobulin E; IU, international units; MFNS, mometasone
furoate nasal spray; SE, standard error. *P < 0.05; **P < 0.001 vs
placebo. P values are nominal, not corrected for multiplicity, and
based on the LS mean differences in AUC0-16 between patients in
the dupilumab group vs the placebo group
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(mean changes from baseline shown in Figure 1). The mean AUC0‐16
for changes from baseline values, when adjusted for covariates, was
significantly lower vs placebo for levels of eotaxin‐3 (LS mean AUC0-
16 [±SE]: −30.06 [5.9] vs −0.86 [6.6] pg/mL; P = 0.0008) and total
IgE (−7.90 [1.9] vs −1.86 [2.1] IU/mL; P = 0.0221) in nasal secretions
of the overall population. The decrease in ECP in the dupilumab
group compared to placebo did not reach statistical significance
(−5.82 [4.3] vs −3.07 [4.6] ng/mL; P = 0.6364). In the dupilumab
group, the mean absolute total IgE, ECP, and eotaxin‐3 concentra-
tions in nasal secretions at baseline were numerically higher than
in the placebo group and declined over time, reaching concentra-
tions either similar to or lower than the placebo group at Week 16
(Table S3)
3.4 | Clinical responses in biopsy subgroup
In the biopsy subgroup (and consistent with that previously reported
for the overall study population32), dupilumab significantly improved
radiographic and patient‐reported measures of disease activity after
16 weeks of treatment vs placebo, including the Lund‐Mackay total
score, percentage of maxillary sinus volume occupied by disease,
SNOT‐22 score, sinusitis symptom severity assessed by the visual
analog scale, and sense of smell assessed by UPSIT, and significantly
reduced circulating concentrations of total IgE and eotaxin‐3
(P < 0.05 for all; Table 1). In this small subset of patients,
improvements in bilateral endoscopic NPS, peak nasal inspiratory
flow in the morning, and nasal congestion or obstruction in the
morning and posterior rhinorrhea in the morning, as well as shifts in
blood eosinophil counts and serum TARC on dupilumab, were not
significantly different with dupilumab vs placebo (Table 1).
3.5 | Tissue homogenate analysis
Dupilumab treatment was associated with significantly lower total
IgE (P = 0.023), ECP (P = 0.008), eotaxin‐2 (P = 0.008), eotaxin‐3
(P = 0.031), PARC (P = 0.016), and IL‐13 (P = 0.031) concentrations
in tissue homogenates of the biopsy subgroup (n = 8) at the end of
treatment compared with baseline (Figure 2). No significant differ-
ences were found in the levels of IL‐6, IL‐1β, eotaxin‐1, IL‐4, IL‐5,
IL‐10, IL‐17, IL‐33, TNF‐α, or TARC compared with baseline for
dupilumab (Table S4). Furthermore, significant differences in median
changes from baseline with dupilumab vs placebo treatment at
Week 16 were found for eotaxin‐1 (P < 0.05), PARC (P < 0.01),
and ECP (P < 0.01) (Figure 3). No significant differences were
found for IL‐6, IL‐33, SE‐IgE, TARC, total IgE, eotaxin‐2 and 3, IL‐
1b, IL‐4, IL‐5, IL‐6, IL‐10, IL‐13, IL‐17, and IL‐33 (Table S5). Overall,
no consistent modulation pattern was observed in the placebo
group between baseline and end of treatment for any of these
biomarkers in the tissue homogenates, with a limited sample size








F IGURE 2 Biomarker concentrations in
the nasal polyp tissue biopsies of patients
with CRSwNP in the biopsy subgroup.
Concentrations at baseline and Week 16
(end of treatment) in the dupilumab (n = 8)
and placebo (n = 4) groups. (A) Total IgE,
(B) ECP, (C) eotaxin‐2, (D) eotaxin‐3,
(E) PARC, and (F) IL‐13. ECP, eosinophil
cationic protein; IgE, immunoglobulin E;
IL, interleukin; PARC, pulmonary and
activation‐regulated chemokine. P values
for end of treatment vs baseline are
reported
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4 | DISCUSSION
CRSwNP is characterized by a type 2‐predominant eosinophilic
endotype in most patients. The presence of high levels of total IgE
and IL‐5 in the nasal tissues and secretions of patients with
CRSwNP, along with increased recognition of their respective roles
in inflammation, has led to the testing of mAbs specifically targeting
IgE (omalizumab) or IL‐5 (mepolizumab) in trials. These therapeutic
agents reduced the signs and symptoms of CRSwNP.18,19,33,34
However (with the exception of periostin), local reductions in IL‐5,
ECP, or total IgE levels in nasal secretions and homogenates were
not demonstrated with these therapeutic agents.34,35 We recently
reported that dupilumab, an IL‐4Rα inhibitor that blocks IL‐4 and
IL‐13 signaling, was well tolerated, reduced polyp size, and rapidly
improved smell in patients with CRSwNP.32 The post hoc analyses
reported here were conducted to further investigate the local effects
of dupilumab on eosinophilic inflammation and obtain more informa-
tion on the relationship between local and serum levels of type 2
chemokines and total IgE in patients with CRSwNP.
Dupilumab treatment was associated with a significant decrease
in biomarkers of type 2 inflammation, including total IgE and
eotaxin‐3, in nasal secretions, as well as a decrease in ECP that did
not reach statistical significance, vs placebo. In nasal polyp homoge-
nates, dupilumab significantly reduced total IgE, the chemokines
eotaxin‐2, eotaxin‐3, and PARC, and ECP concentrations at Week 16
compared with baseline, and eotaxin‐1, ECP, and PARC only when
compared as mean changes from baseline at Week 16 vs placebo;
similar trends were not observed with placebo. These data suggest
that dupilumab not only reduces mucosal IgE production via
antagonism of IL‐4Rα signaling, but most likely also affects the eosi-
nophil pathway locally via suppression of eosinophil chemokine
release; this is consistent with prior observations of increased levels
of total IgE, ECP, and eosinophils in nasal polyps that may respond
to therapy.5 We have previously reported that dupilumab markedly
lowers total IgE and eotaxin‐3 levels in the blood of patients with
CRSwNP.32 Thus, dupilumab demonstrates both systemic and local
effects on these markers of type 2 inflammation in CRSwNP.
Eosinophil cationic protein is a cytotoxic ribonuclease produced
and released by degranulating eosinophils. ECP concentrations are
associated with the number of activated eosinophils in the blood.36
Elevation in eosinophil activity has not been completely elucidated,
though it is elevated in CRSwNP and asthma, as well as other eosi-
nophilic inflammatory diseases.6,36 An increase in ECP concentra-
tions in nasal mucosa may cause epithelial damage. Supporting this
hypothesis, high concentrations of ECP have been reported in recur-
rent CRSwNP.6,36 Dupilumab treatment resulted in a significant
reduction in ECP concentrations in nasal polyp tissue at Week 16
compared with baseline, with a decline in ECP levels that did not
reach statistical significance in nasal secretions, suggesting a








F IGURE 2 Continued
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insufficient tissue, the effect of dupilumab on local eosinophil counts
could not be determined.
Dupilumab significantly reduced the concentrations of eotaxin
chemokines in both plasma32 and nasal secretions in patients with
CRSwNP. Eotaxin levels are elevated in CRSwNP and other allergic
and eosinophilic diseases such as asthma and AD.37 The eotaxin
family consists of eotaxin‐1 (CCL11), eotaxin‐2 (CCL24), and eotaxin‐
3 (CCL26), all of which are potent chemotactic factors for eosino-
phils and other inflammatory cells that express their receptors, and
are released from epithelial cells following exposure to IL‐4 and
IL‐13.38,39 Eotaxins act on eosinophils and T lymphocytes to prolong
the survival of eosinophils via the production and secretion of type
2‐associated cytokines37 and mediate transepithelial eosinophil
migration and activation.40,41 Eotaxin‐3, in particular, has been
suggested to be an important recruiter of eosinophils in asthma,42
eosinophilic esophagitis,43 and nasal polyposis.44 Inhibiting IL‐4/IL‐13
signaling with dupilumab blockade of IL‐4Rα resulted in a decrease
of eotaxin‐2 in nasal polyp tissue and eotaxin‐3 in both nasal polyp
tissue and secretions.
PARC (also known as CCL18, MIP‐4, AMAC‐1, and DC‐CK1) is
elevated in patients with CRSwNP.45 Secreted by mast cells, mono-
cytes, dendritic cells, and macrophages, its expression is regulated by
IL‐4 and IL‐13, as well as IL‐10. PARC is chemotactic for multiple cell
types, including Th2‐cells, naive T cells, and dendritic cells. PARC is
highly expressed in inflammatory diseases such as asthma and
AD.23,46,47 In this substudy, dupilumab significantly reduced PARC
concentrations in nasal polyp tissue compared with baseline,
suggesting IL‐4 and IL‐13 are key drivers of tissue infiltration of not
only eosinophils, but also other inflammatory cell types implicated in
CRSwNP pathobiology.
Overall, these effects of dupilumab on biomarkers are consistent
with blockade of IL‐4Rα and indicate a local anti‐inflammatory effect
in the nose and sinuses. A possible mechanism for reducing eosino-
phil infiltration and activation in tissues, suggested by reduced levels
of eotaxins in nasal secretions and polyps, may be downregulation of
the chemotactic gradient, signaling eosinophil migration from the
bloodstream into the tissue. Such a mechanism is further supported
by the transient increase in eosinophils observed in blood shortly
after the start of dupilumab treatment.32
Clinical improvements in the subgroup with polyp biopsies
(n = 8) were comparable to those observed in the overall treatment
group (n = 30) before and after 16 weeks of dupilumab treatment
(LS mean differences vs placebo at Week 16 [95% CI] in NPS and
SNOT‐22 score in biopsy subgroup vs total population: −1.06
[−3.43, 1.31] vs −1.55 [−2.43, −0.67] and −31.52 [−55.12, −7.91]
vs −18.11 [−25.62, −10.60], respectively), suggesting that reductions
in local inflammation biomarkers were attended by parallel improve-
ments in symptoms and reduction in polypoid mass, as assessed by
endoscopic exam and CT imaging. However, in contrast to the over-
all population, not all improvements in the biopsy subgroup were sig-
nificant due to the small number of patients in the cohort, and no
analyses were performed assessing associations between individual‐
level improvements in biomarkers with individual‐level reductions in
symptoms and polypoid mass.
Indeed, a limitation of this study was the small cohort of patients
available for nasal secretions and tissue biopsy analyses. In a larger,
ongoing phase 3 study (SINUS‐52; ClinicalTrials.gov Identifier:







F IGURE 3 Biomarker concentrations in the nasal polyp tissue
biopsies of patients with CRSwNP in the biopsy subgroup.
Median changes from baseline at Week 16 (end of treatment) in the
dupilumab (n = 8) and placebo (n = 4) groups in (A) ECP, (B) eotaxin‐1,
and (C) PARC concentrations. CRSwNP, chronic rhinosinusitis with
nasal polyposis; ECP, eosinophil cationic protein; PARC, pulmonary
and activation‐regulated chemokine. P values are nominal, not
corrected for multiplicity. Error bars represent the interquartile range
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expression analyses and cytology of nasal mucosa brushings will be
assessed. Another limitation of this study is that it enrolled almost
exclusively Caucasian patients; as racial and regional differences in
underlying inflammation associated with nasal polyps have been
reported,10 the findings for biomarkers in this study may not be uni-
versally applicable.
Further studies are warranted to investigate dupilumab's mecha-
nisms of action and identify markers of response in greater detail.
5 | CONCLUSIONS
The reduction of multiple inflammatory biomarkers, including total IgE
and markers of eosinophilic inflammation, in both nasal secretions and
polyp tissues of patients with CRSwNP treated with dupilumab, rela-
tive to placebo and baseline, respectively, demonstrated a local effect
of dupilumab on type 2 disease mechanisms, which were consistent
with overall, parallel improvements in nasosinal symptoms and reduc-
tions in polypoid tissue. This suggests that the antagonism of IL‐4Rα
signaling with dupilumab leads to clinical benefits that are mediated
by reductions in underlying type 2 mucosal inflammation, although
further analyses in larger patient populations are required to confirm
these findings. Overall, we demonstrate that dupilumab has a broad
mechanism of action, with its ability to target two central driver
cytokines of type 2 inflammation, which might be more advantageous
than targeting a single type 2 cytokine (eg, IL5 or IL13 alone) or solely
targeting total IgE for the treatment of atopic diseases.
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